The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.

Inclusion Criteria:

• Subjects with relapsing forms of MS defined by 2005 revised McDonald criteria
• Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5

Exclusion Criteria:

• Patients with a manifestation of MS other than relapsing remitting MS
• Patients with a history of chronic disease of the immune system other than MS such as known immunodeficiency syndrome
• History or presence of malignancy in the last 5 years
• Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients
• Diagnosis of macular edema during Screening Phase
• Patients with active systemic bacterial, viral or fungal infections
• Negative for varicella-zoster virus IgG antibodies at Screening
• Patients who have been treated with cladribine, cyclophosphamide or mitoxantrone at any time
• History of cardiovascular disorder
• Women of child-baring potential and inadequate contraception

Other protocol-defined inclusion/exclusion criteria may apply